AU2003226496A1 - Pharmaceutical combination of the cox-2 inhibitor etodolac and opioids - Google Patents
Pharmaceutical combination of the cox-2 inhibitor etodolac and opioidsInfo
- Publication number
- AU2003226496A1 AU2003226496A1 AU2003226496A AU2003226496A AU2003226496A1 AU 2003226496 A1 AU2003226496 A1 AU 2003226496A1 AU 2003226496 A AU2003226496 A AU 2003226496A AU 2003226496 A AU2003226496 A AU 2003226496A AU 2003226496 A1 AU2003226496 A1 AU 2003226496A1
- Authority
- AU
- Australia
- Prior art keywords
- etodolac
- opioids
- cox
- inhibitor
- pharmaceutical combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0206505.0 | 2002-03-19 | ||
GBGB0206505.0A GB0206505D0 (en) | 2002-03-19 | 2002-03-19 | Pharmaceutical combination |
PCT/GB2003/001182 WO2003080183A1 (en) | 2002-03-19 | 2003-03-19 | Pharmaceutical combination of the cox-2 inhibitor etodolac and opioids |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2003226496A1 true AU2003226496A1 (en) | 2003-10-08 |
Family
ID=9933308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003226496A Abandoned AU2003226496A1 (en) | 2002-03-19 | 2003-03-19 | Pharmaceutical combination of the cox-2 inhibitor etodolac and opioids |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2003226496A1 (en) |
GB (1) | GB0206505D0 (en) |
WO (1) | WO2003080183A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2665042T3 (en) * | 2008-02-18 | 2018-04-24 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds that bind to sigma receptor ligands for the treatment of neuropathic pain that develops as a result of chemotherapy |
EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
CN103860551A (en) * | 2012-12-10 | 2014-06-18 | 鲁南制药集团股份有限公司 | Pharmaceutical composition containing etodolac and tramadol hydrochloride and application thereof |
EP3082782A1 (en) | 2013-12-17 | 2016-10-26 | Laboratorios Del. Dr. Esteve, S.A. | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2177644T3 (en) * | 1994-04-12 | 2002-12-16 | Arakis Ltd | PROCEDURE FOR THE RESOLUTION OF ETODOLAC USING GLUCAMINE DERIVATIVES. |
US5840731A (en) * | 1995-08-02 | 1998-11-24 | Virginia Commonwealth University | Pain-alleviating drug composition and method for alleviating pain |
RS49982B (en) * | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor |
FR2770131A1 (en) * | 1997-10-27 | 1999-04-30 | Union Pharma Scient Appl | Analgesic combinations of a cyclooxygenase-2 inhibitor and acetaminophen or an opiate having synergistic activity |
US6007841A (en) * | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
AU1398899A (en) * | 1998-11-12 | 2000-06-05 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with centrally acting analgesics |
CN1227001C (en) * | 1999-09-10 | 2005-11-16 | 兰贝克赛实验室有限公司 | Extended release formulation of etodolac |
BRPI0108380B8 (en) * | 2000-02-08 | 2021-05-25 | Euro Celtique S/A | adulteration resistant opioid agonist formulas, method of decreasing the abuse of an opioid agonist in an oral dosage formula, method of preparing an oral dosage formula, and pain management method |
US20020187995A1 (en) * | 2001-05-01 | 2002-12-12 | Fitzgerald Desmond Joseph | Methods for use in modifying the perception of pain |
-
2002
- 2002-03-19 GB GBGB0206505.0A patent/GB0206505D0/en not_active Ceased
-
2003
- 2003-03-19 WO PCT/GB2003/001182 patent/WO2003080183A1/en not_active Application Discontinuation
- 2003-03-19 AU AU2003226496A patent/AU2003226496A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003080183A1 (en) | 2003-10-02 |
GB0206505D0 (en) | 2002-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003275311A1 (en) | Solid micro-perforators and methods of use | |
AU2003303128A1 (en) | Inhibitors and methods of use thereof | |
AU2003217870A1 (en) | Pini-modulating compounds and methods of use thereof | |
AU2003225668A1 (en) | Pin1-modulating compounds and methods of use thereof | |
AU2003225669A1 (en) | Pin1-modulating compounds and methods of use thereof | |
AU2003219619A1 (en) | Detection of polymorphisms | |
AU2003235676A1 (en) | Tricyclic-bis-enone derivatives and methods of use thereof | |
AU2003213673A1 (en) | Pin1-modulating compounds and methods of use thereof | |
AU2003202263A1 (en) | Roh-kinase inhibitors | |
IL172752A0 (en) | Cox-2 and faah inhibitors | |
AU2003225756A1 (en) | Silica-based materials and methods | |
AU2003220437A1 (en) | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | |
EG24845A (en) | Pharmaceutical combinations of cox-2 inhibitors and opiates | |
AU2003226496A1 (en) | Pharmaceutical combination of the cox-2 inhibitor etodolac and opioids | |
AU2003299943A1 (en) | Heterocycles and uses thereof | |
AU2002338734A1 (en) | Use of phosphorodiesterase IV inhibitors | |
AU2003222058A1 (en) | Materials and methods for inhibiting wip-1 | |
AU2003297612A1 (en) | 2-substituted-3-propenamide derivatives and methods of using the same | |
AU2003295638A1 (en) | NOVEL INHIBITORS OF Beta-LACTAMASE | |
AU2003287802A1 (en) | Palpometer and methods of use thereof | |
AU2003251513A1 (en) | Rsk inhibitors and therapeutic uses thereof | |
AU2003285686A1 (en) | Glycoisoforms of adiponectin and uses thereof | |
AU2003294883A1 (en) | Combinations of valsartan with cox-2 inhibitors | |
AU2003279800A1 (en) | Sulfatases and methods of use thereof | |
AU2003302173A1 (en) | Spirotetrathiocarbamates and spirooxothiocarbamates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |